Spondyloarthritis & psoriatic arthritis
Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French health insurance database (SNDS)
An erratum to this article was published (RMD Open, 12 Jan 2024 ↗)
Authors' conclusion
The treatment persistence was lower for women than men for TNFi and IL17i but not for IL12/23i, IL23i or JAKi.
Study context
- Population
- Adults with psoriatic arthritis (PsA) who were new users of targeted therapies during 2015–2021, French health insurance database
- Participants
- 14,778 adults
- Exposure
- Women vs men initiating targeted therapies for PsA
- Womenn = 8,475
- Menn = 6,303reference
- Outcome
- Persistence of each class of targeted therapies (time from treatment initiation to discontinuation), by sex
Methodological detailsnationwide, administrative healthcare database (SNDS) linked to hospital discharge database, new users, Kaplan-Meier, multivariate frailty models
- Nationwide
- Administrative healthcare database (SNDS) linked to hospital discharge database
- New users
- Kaplan-Meier
- Multivariate frailty models
Main finding
As reported in the abstract
Treatment persistence (discontinuation), by targeted therapy class
HRa
- TNFi
- 1.4 (99% CI 1.3–1.5)
- IL17i
- 1.2 (99% CI 1.1–1.3)
- IL12/23i
- 1.1 (99% CI 0.9–1.3)
- IL23i
- 1.1 (99% CI 0.7–1.5)
- Janus kinase inhibitor (JAKi)
- 1.2 (99% CI 0.9–1.6)
Observational data: associations, not effects.
Further findings
Overall persistence · 1 year
Overall persistence · 3 years
Original publication
Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French health insurance database (SNDS). RMD Open. Published 19 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →